Affiliation:
1. Department of Pathology, Hershey Medical Center, Hershey, Pennsylvania 17033
Abstract
ABSTRACT
We tested the propensity of three quinolones to select for resistant
Streptococcus pneumoniae
mutants by determining the mutant prevention concentration (MPC) against 100 clinical strains, some of which harbored mutations in type II topoisomerases. Compared with levofloxacin and gemifloxacin, moxifloxacin had the lowest number of strains with MPCs above the susceptibility breakpoint (
P
< 0.001), thus representing a lower selective pressure for proliferation of resistant mutants. Only moxifloxacin gave a 50% MPC (MPC
50
) value (1 μg/ml) within the susceptible range.
Publisher
American Society for Microbiology
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology